Akebia Therapeutics Inc. [NASDAQ: AKBA] traded at a high on 10/09/20, posting a 5.42 gain after which it closed the day’ session at $3.11. The company report on October 10, 2020 that Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined.
– Phase 3 data from INNO2VATE program in dialysis and PRO2TECT program in non-dialysis accepted for oral presentation.
– Ten additional abstracts accepted.
The results of the trading session contributed to over 5923463 shares changing hands. Over the past one week, the price volatility of Akebia Therapeutics Inc. stands at 6.93% while the volatility over the past one month is 7.28%.
The market cap for AKBA stock reached $416.71 million, with 136.91 million shares outstanding and 134.72 million shares in the current float. Compared to the average trading volume of 5.03M shares, AKBA reached a trading volume of 5923463 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Akebia Therapeutics Inc. [AKBA]?
Needham have made an estimate for Akebia Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 14, 2019. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $19 to $17. The new note on the price target was released on August 06, 2019, representing the official price target for Akebia Therapeutics Inc. stock. Previously, the target price had yet another drop from $23 to $21, while H.C. Wainwright kept a Buy rating on AKBA stock.
The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.40, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 1.22. The Price to Book ratio for the last quarter was 1.15, with the Price to Cash per share for the same quarter was set at 2.20.
How has AKBA stock performed recently?
Akebia Therapeutics Inc. [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.91. With this latest performance, AKBA shares gained by 19.62% in over the last four-week period, additionally sinking by -54.93% over the last 6 months – not to mention a drop of -24.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKBA stock in for the last two-week period is set at 36.56, with the RSI for the last a single of trading hit 51.70, and the three-weeks RSI is set at 31.70 for Akebia Therapeutics Inc. [AKBA]. The present Moving Average for the last 50 days of trading for this stock 6.44, while it was recorded at 2.85 for the last single week of trading, and 8.71 for the last 200 days.
Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48.
Return on Total Capital for AKBA is now -49.62, given the latest momentum, and Return on Invested Capital for the company is -49.32. Return on Equity for this stock declined to -54.27, with Return on Assets sitting at -29.74. When it comes to the capital structure of this company, Akebia Therapeutics Inc. [AKBA] has a Total Debt to Total Equity ratio set at 27.44. Additionally, AKBA Total Debt to Total Capital is recorded at 21.53, with Total Debt to Total Assets ending up at 14.05. Long-Term Debt to Equity for the company is recorded at 26.18, with the Long-Term Debt to Total Capital now at 20.54.
Reflecting on the efficiency of the workforce at the company, Akebia Therapeutics Inc. [AKBA] managed to generate an average of -$776,831 per employee. Receivables Turnover for the company is 12.07 with a Total Asset Turnover recorded at a value of 0.36.Akebia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.30.
Earnings analysis for Akebia Therapeutics Inc. [AKBA]
With the latest financial reports released by the company, Akebia Therapeutics Inc. posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.43/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AKBA.
Insider trade positions for Akebia Therapeutics Inc. [AKBA]
There are presently around $345 million, or 80.70% of AKBA stock, in the hands of institutional investors. The top three institutional holders of AKBA stocks are: BAUPOST GROUP LLC/MA with ownership of 15,000,000, which is approximately -14.422% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 11,363,863 shares of the stock with an approximate value of $35.34 million in AKBA stocks shares; and VANGUARD GROUP INC, currently with $22.77 million in AKBA stock with ownership of nearly 24.387% of the company’s market capitalization.
Positions in Akebia Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 121 institutional holders increased their position in Akebia Therapeutics Inc. [NASDAQ:AKBA] by around 27,739,138 shares. Additionally, 59 investors decreased positions by around 9,110,166 shares, while 22 investors held positions by with 74,060,689 shares. The mentioned changes placed institutional holdings at 110,909,993 shares, according to the latest SEC report filing. AKBA stock had 47 new institutional investments in for a total of 11,815,119 shares, while 15 institutional investors sold positions of 1,366,490 shares during the same period.